VITAMIN D DEFICIENCY IN ACUTE CORONARY SYNDROME – CLINICALLY RELEVANT OR INCIDENTAL FINDING?

Marijana Knežević Praveček1, Željka Vuković-Arar2, Blaženka Miškić3, Izral Hadžibegović1

1Department of Cardiology, Dr. Josip Benčević General Hospital, School of Medicine, Josip Juraj Strossmayer University, Osijek, Croatia
2Department of Ophthalmology, Dr. Josip Benčević General Hospital, School of Medicine, Josip Juraj Strossmayer University, Osijek, Croatia
3Department of Endocrinology, Dr. Josip Benčević General Hospital, School of Medicine, Josip Juraj Strossmayer University, Osijek, Croatia

SUMMARY

Objective: Vitamin D deficiency has been associated with cardiovascular disease. The aim of this study was to determine serum concentration of 25-hydroxyvitamin D (25(OH)D) in patients with acute coronary syndrome (ACS) and to assess the prognostic role of serum vitamin D level in ACS patients during 3-year follow up.

Methods: The study included 60 ACS patients hospitalized at cardiology department for ACS between March 2012 and October 2012, and 60 age- and sex-matched control patients without ACS. Standard laboratory testing and vitamin D determination were performed in all study patients. In addition, ACS patients underwent coronaryography and were followed-up for 36 months of ACS for major adverse cardiac events (MACE).

Results: Patients with ACS had a statistically significantly lower mean 25(OH)D level as compared with control group (35.19 nmol/L vs. 58.08 nmol/L, p < 0.001). The lowest mean level of 25(OH)D was recorded in diabetic patients with ACS (30.45 nmol/L). ACS patients were divided into three subgroups according to coronaryography findings: single vessel, double vessel and triple vessel coronary artery disease (CAD) with respective serum levels of 25(OH)D of 36.44 nmol/L, 33.65 nmol/L and 31.70 nmol/L. During 36-month follow up, the event-free survival rate was 60% in the ACS group. The ACS patients having sustained MACE during follow up had low serum level of 25(OH)D in the acute phase; however, the difference from ACS patients without MACE during follow up did not reach statistical significance (32.64 nmol/L vs. 37.01 nmol/L).

Conclusions: Patients with ACS have low vitamin D level, which is lowest in diabetic patients with ACS. However, during 3-year follow up, vitamin D failed to prove useful as a prognostic biomarker in ACS patients.

Key words: acute coronary syndrome, coronary angiography, 25-hydroxyvitamin D, diabetes, vitamin D deficiency

Address for correspondence: M. Knežević Praveček, Department of Cardiology, Dr. Josip Benčević General Hospital, Andrije Štampara 42, HR-35000 Slavonski Brod, Croatia. E-mail: marijana@aip.hr

https://doi.org/10.21101/cejph.a4577

INTRODUCTION

Vitamin D is a precursor of the steroid hormone calcitriol which is necessary for mineral homeostasis and bone metabolism (1). Upon vitamin D discovery in almost all body cells, such as immune system, vascular and myocardial cells, a more diversified role of vitamin D than previously believed has been recognized. This has resulted in extensive research into the role of vitamin D in the pathogenesis of chronic non-skeletal diseases such as infectious, autoimmune, malignant, and cardiovascular diseases (CVD) (2).

Cardiovascular risk factors such as arterial hypertension, obesity, dyslipidemia, and diabetes mellitus (DM), and the resulting CVD including acute coronary syndrome (ACS), coronary artery disease (CAD) and stroke are the most prevalent illnesses and the leading causes of death worldwide. Therefore, it is of utmost importance to determine the role of vitamin D in CVD.

Vitamin D deficiency has been recorded all over the world. Estimates of vitamin D status in various European countries show great differences. According to literature data, the prevalence of vitamin D deficiency is between 2% and 30% in adult European population; however, some studies report a figure as high as 75% in elderly institutionalized individuals. Accordingly, vitamin D deficiency has grown into a major public health problem (3).

The 1,25(OH)2D is a bioactive form of vitamin D, while 25-hydroxyvitamin D (25(OH)D) is the best indicator of vitamin D status. Serum concentration of 25(OH)D reflects the level of vitamin D synthesized in the dermis as a function UV radiation and dietary vitamin D intake. Cold season, old age, female sex, obesity, dark skin, inadequate sun exposure, fat malabsorption, and poor dietary habits along with the absence of dietary vitamin D enrichment are the major risk factors for vitamin D deficiency. In scientific community, there is no consensus on the adequate vitamin D level. The opinions concerning optimal and borderline 25(OH)D levels vary considerably. According to the Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, serum 25(OH)D level ≥50 nmol/L is considered normal, 30–50 nmol/L inadequate and ≤30 nmol/L deficient. The recommended level of 50 nmol/L is based on evidence on the vitamin D level necessary for bone health. On
the other hand, according to the recommendations issued by the American Geriatrics Society, International Osteoporosis Foundation and American Association of Clinical Endocrinologists, serum 25(OH)D level < 50 nmol/L is considered inadequate and > 75 nmol/L appropriate to reduce the risk of fractures and falls in the elderly (4, 5). There is ever more evidence pointing to a U-shaped curve for several vitamin D level associated health outcomes, including CVD and all-cause mortality, the risk being lowest at moderate but increased at low and high 25(OH)D levels (6).

Vitamin D deficiency was found in patients with ACS and preliminary studies suggest it to be potentially associated with prognosis as well. However, convincing evidence confirming the impact of vitamin D insufficiency or deficiency on ACS patient morbidity and mortality is still lacking (7). The biological mechanism of vitamin D deficiency in ACS is not simple; we can only speculate on a dual effect of vitamin D in ACS, i.e. its direct immunomodulatory action and indirect action on the known cardiovascular risk factors.

There is evidence for vitamin D to suppress the renin-angiotensin system and to influence endothelial function, inflammatory processes, platelet function, insulin resistance, and blood pressure (8). All these effects are highly relevant in ACS influencing the patient clinical course. In addition, low vitamin D level has been associated with ventricular dysfunction and cardiac remodeling following ACS, as well as with heart failure and sudden cardiac death (9–12). Therefore, it appears that vitamin D level can influence both short-term and long-term outcomes in ACS patients.

The aim of the present study was to analyze serum 25(OH)D levels in ACS patients in comparison to ACS-free control group, to assess the association of CAD and serum 25(OH)D levels in ACS patients, and to evaluate the ACS patient prognosis according to serum 25(OH)D levels for the first time in a homogeneous Caucasian population in Croatia.

MATERIALS AND METHODS

Study Population

The study included 60 patients treated for ACS at Dr Josip Benčević General Hospital in Slavonski Brod, Croatia, from March 2012 till October 2012, and 60 subjects not treated for any form of ischaemic heart disease before enrolment in the study as a control group. We included patients with ST elevation myocardial infarction (STEMI) and those with non-ST elevation acute coronary syndrome (NSTE-ACS). The inclusion criteria for ACS group were age (30–70 years); guideline confirmed acute myocardial infarction (STEMI) and those with non-ST elevation study as a control group. We included patients with ST elevation any form of ischaemic heart disease before enrolment in the Benčević General Hospital in Slavonski Brod, Croatia, from free from ACS but with at least one of the established risk factors for CAD, including hypertension, DM, obesity, smoking, and hyperlipidemia. Individuals with known recent or previous ACS, or established CVD or chronic disease such as renal or hepatic disease, hyperthyroidism or hyperparathyroidism, sarcoidosis, tuberculosis, autoimmune disease, malabsorption, bone disease, malignancy, pregnancy or lactation, immobility for more than one week, recent vitamin D administration (oral in the last two weeks or injection in the last two months), and receiving drugs affecting vitamin D and calcium metabolism (e.g. corticosteroids or antiepileptic drugs) were excluded. In order to minimize the confounding effect of seasonal fluctuation of 25(OH)D concentration, we tended to involve an equal number of patients each month.

Blood samples were obtained on patient admission. Creatinine, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, glucose, and total calcium were determined colorimetrically on an AU 680 (Beckman Coulter, Fullerton, USA) auto-analyzer using respective reagents of the same manufacturer. The following demographic and medical data were recorded: age, gender, body mass index (body weight in kilograms divided by the square of height in metres, kg/m², BMI), smoking habit, DM, and hypertension. Smoking habit was classified into two categories: current/ex-smoker and non-smoker. Diabetes mellitus was classified as newly detected DM (fasting blood glucose > 7 mmol/L) and known DM treated with insulin or oral hypoglycemic agents. Arterial hypertension included newly detected hypertension with diastolic blood pressure > 90 mm Hg (> 85 mm Hg in diabetic patients) or systolic blood pressure > 145 mm Hg (> 130 mm Hg in diabetic patients) and known hypertension treated with antihypertensive therapy.

Plasma parathyroid hormone (PTH) and vitamin D were determined by the electrochemiluminescence method on an Elecsys 2010, Cobas e 411 (Roche Diagnostics, Mannheim, Germany) analyzer with respective reagents. The Institute of Medicine Food and Nutrition Board Dietary Reference Intakes for Vitamin D and Nutrition Board Dietary Reference Intakes for Calcium and Magnesium, 2010, both from the National Academies Press, were used to determine vitamin D and calcium levels as normal distribution across the sample and within particular groups.

Statistics

Categorical variables were presented descriptively and tested by χ²-test for between-group differences. Shapiro-Wilk test was employed to test the normality of result distribution of all numerical continuous variables according to the number of patients per group. Of all the variables observed, only vitamin D value showed normal distribution across the sample and within particular groups,
whereas all other variables failed to show normal distribution.

Numerical variables with normal distribution were presented with the mean and standard deviation (SD), while between-group differences were analyzed by Student’s t-test. Differences in numerical variables with normal distribution among more than two groups were analyzed by ANOVA with post hoc analysis using Tukey HSD post hoc test.

Numerical variables with non-normal distribution were presented with median value and minimal to maximal value range. Between-group differences in numerical variables with non-normal distribution were analyzed by Mann-Whitney test for two independent samples.

Correlations between continuous numerical variables with normal distribution were tested by Pearson correlation test, whereas the variables with non-normal distribution were tested by Spearman correlation test. Correlation of the study variables with vitamin D values within the groups was analyzed by linear regression.

The level of statistical significance was set at $p < 0.05$. Statistical analysis was performed by use of the SPSS for Windows 11.0.3 software (SPSS Inc., Chicago, IL, USA).

RESULTS

The study included 60 ACS patients and 60 patients without ACS as a control group. There were no significant differences in demographic and relevant clinical characteristics between the two groups of patients, except for a statistically significantly higher proportion of smokers in the ACS group as compared with the control group (Table 1).

The ACS group included 36 (60%) patients with STEMI and 24 (40%) patients with NSTE-ACS. According to the coronary disease severity assessed by coronarography, patients were divided into subgroups with SVCAD – 39 (68%), DVCAD – 15 (26%) and MVCAD – 3 (6%).

The mean serum concentration of 25(OH)D of 35.19 ± 17.54 nmol/L measured in ACS patients was statistically significantly lower in comparison with control group, where it was 58.08 ± 16.29 nmol/L (Student’s t-test, $p < 0.001$) (Table 1).

Use of reference values for vitamin D sufficiency, insufficiency and deficiency yielded a statistically significantly higher rate of vitamin D insufficiency among ACS patients as compared with control group ($\chi^2$-test, $p < 0.001$). Vitamin D deficiency was recorded in as many as 20% of ACS patients and none of control subjects (Fig. 1). There was no statistically significant difference in 25(OH)D serum levels within ACS and control groups according to age and other relevant clinical characteristics, except for DM (Table 1). According to gender, a lower mean 25(OH)D level was recorded in female ACS patients (30.85 nmol/L vs. 37.35 nmol/L), but not in control female patients, where a higher mean 25(OH)D level was measured (61.94 nmol/L vs. 55.90 nmol/L); these differences did not reach statistical significance either (Student’s t-test, $p > 0.05$).

In the ACS group, the mean 25(OH)D level was lower in patients with DM comorbidity. In addition, the lowest mean 25(OH)D level of 30.45 ± 15.05 nmol/L was recorded in the subgroup of ACS+DM patients as compared with all other study groups. A similar tendency toward a lower mean 25(OH)D level

![Table 1. Baseline characteristics of study subjects](image)

**Table 1. Baseline characteristics of study subjects**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Group of subjects, N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Acute coronary syndrome N = 60</td>
</tr>
<tr>
<td>Gender, male, n (%)</td>
<td>40 (67)</td>
</tr>
<tr>
<td>Age, median (range)</td>
<td>58 (34–72)</td>
</tr>
<tr>
<td>BMI, median (range)</td>
<td>28 (20–34)</td>
</tr>
<tr>
<td>Diabetes mellitus, n (%)</td>
<td>21 (35)</td>
</tr>
<tr>
<td>Smoking, n (%)</td>
<td>39 (67)</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>43 (72)</td>
</tr>
<tr>
<td>Dyslipidemia, n (%)</td>
<td>52 (87)</td>
</tr>
<tr>
<td>Creatinine, mean ± SD (μmol/L)</td>
<td>89.98 ± 13.12</td>
</tr>
<tr>
<td>Total cholesterol, mean ± SD (mmol/L)</td>
<td>5.45 ± 1.21</td>
</tr>
<tr>
<td>Triglycerides, mean ± SD (mmol/L)</td>
<td>2.10 ± 1.25</td>
</tr>
<tr>
<td>LDL cholesterol, mean ± SD (mmol/L)</td>
<td>3.22 ± 1.16</td>
</tr>
<tr>
<td>HDL cholesterol, mean ± SD (mmol/L)</td>
<td>1.00 ± 0.30</td>
</tr>
<tr>
<td>Calcium, mean ± SD (mmol/L)</td>
<td>2.29 ± 0.14</td>
</tr>
<tr>
<td>Phosphorus, mean ± SD (mmol/L)</td>
<td>1.10 ± 0.19</td>
</tr>
<tr>
<td>PTH, mean ± SD (pg/mL)</td>
<td>36.14 ± 10.69</td>
</tr>
<tr>
<td>25 OH vitamin D, mean ± SD (nmol/L)</td>
<td>35.19 ± 17.54</td>
</tr>
<tr>
<td>SVCAD, n (%)</td>
<td>39 (68)</td>
</tr>
<tr>
<td>DVCAD, n (%)</td>
<td>15 (26)</td>
</tr>
<tr>
<td>MVCAD, n (%)</td>
<td>3 (6)</td>
</tr>
<tr>
<td>PCI, n (%)</td>
<td>46 (77)</td>
</tr>
<tr>
<td>CABG, n (%)</td>
<td>9 (15)</td>
</tr>
<tr>
<td>OMT, n (%)</td>
<td>5 (8)</td>
</tr>
<tr>
<td>Total MACE, n (%)</td>
<td>24 (40)</td>
</tr>
</tbody>
</table>

*chi square test, $p < 0.05$
†Student’s t-test, $p < 0.001$


![Fig. 1. Significant differences in the proportion of patients with 25(OH)D sufficiency, insufficiency and deficit between ACS and control groups of patients.](image)
of 46.60±19.26 nmol/L in DM patients was also recorded in control group, and this difference was statistically significant (Student’s t-test, p<0.05) (Fig. 2). In the group of ACS patients, there was no difference in serum 25(OH)D level between STEMI and NSTEMI-ACS patients.

According to CAD severity, the lowest 25(OH)D mean level was measured in patients with MVCAD (31.70 nmol/L). The mean 25(OH)D levels were lower in patients with DVCAD as compared with those with SVCAD (33.65 nmol/L vs. 36.44 nmol/L), however, the difference was not statistically significant (one-way ANOVA, p=0.818; post hoc Tukey HSD test).

There were no significant correlations of 25(OH)D concentration with BMI, LDL-cholesterol, HDL-cholesterol and triglycerides, but they differed greatly between the ACS group and control group; 25(OH)D correlation with LDL-cholesterol and HDL-cholesterol was positive in ACS patients but negative in control patients. Also, correlation of 25(OH)D and triglycerides was negative in ACS patients but positive in control patients. However, none of these correlations was statistically significant. Positive correlation of 25(OH)D and LDL-cholesterol in ACS patients was close to statistical significance; it was submitted to linear regression analysis, which yielded a weak correlation of these two variables, based on the linear regression curve shape with a great number of outliers, with a low level of correlation ($R^2=0.059$).

During 36-month follow up, 40% of study patients suffered MACE. Serum level of 25(OH)D in acute phase was low in ACS patients with MACE, but difference from ACS patients without MACE was not statistically significant (32.64 nmol/L vs. 37.01 nmol/L) (Fig. 3). The number of ACS patients with MACE recorded during follow up was comparable in all three patient subgroups with normal, insufficient and deficient 25(OH)D serum levels (Fig. 4).

**DISCUSSION**

The present study conducted in Croatia compared serum 25(OH)D levels in ACS patients and age-matched non-ACS patients as a control group. Serum 25(OH)D level was statistically significantly lower in the former group of patients. Our results on the high prevalence of vitamin D deficiency or insufficiency in ACS patients (80%) are consistent with literature data associating CVD and numerous CVD risk factors with 25(OH)D deficiency (6, 8–10, 16). In addition to the high prevalence of 25(OH)D deficiency in ACS patients, our study confirmed association of demographic characteristics including female gender and DM with vitamin D deficiency (17).

It should be noted that the study included a homogeneous Caucasian population. Geographically, Croatia lies mostly between latitudes 42° and 46° N, thus preventing vitamin D production in the skin by sun exposure from October to March. Being aware of vitamin D seasonal variation, the study was conducted from March till October (18).

Study results confirmed significant association between low vitamin D level and higher prevalence of DVCAD and MVCAD.
in ACS. In their comparison study, Correia et al. demonstrated the association of vitamin D insufficiency and coronary artery atherosclerosis in stable coronary disease (19), while Verdoia et al. reported a significant association of vitamin D deficiency and severe CVD, in particular in patients with 25(OH)D level <24.96 nmol/L (20).

The possible association of vitamin D deficiency and ACS should be additionally elucidated in future studies. The potential mechanisms by which vitamin D insufficiency might lead to an increased cardiovascular risk, directly or indirectly leading to hyperparathyroidism, may include activation of the renin-angiotensin system and impaired insulin synthesis, secretion and sensitivity, thus influencing glycemic control and favouring development of DM (21). Low 25(OH)D levels have also been associated with an increased risk of macrovascular and microvascular complications in DM type 2 (22).

Other potential sequels of vitamin D deficiency include exacerbation of atherosclerosis, inflammation, and precipitation of arterial calcification. Vitamin D deficiency has been associated with endothelial dysfunction, which in turn is associated with an increased risk of cardiovascular events (23).

In our study, we demonstrated low serum vitamin D level in the acute phase of ACS; however, we failed to confirm the association of low serum vitamin D level and MACE in ACS patients during 3-year follow up. In recent years, there has been even greater interest in the possible sequels of low vitamin D level in ACS. De Metrio et al. reported the possible correlation between low vitamin D level and increased in-hospital mortality; however, due to the small sample size, they found no difference in mortality between ACS patients with normal and low vitamin D levels (24). In another study, the authors pointed to the possible independent association of vitamin D deficiency and in-hospital cardiovascular mortality (19). The largest study assessing vitamin D level and prognosis in ACS patients, conducted by Ng et al., found the lowest vitamin D concentration to be associated with long-term nonfatal MACE in ACS patients (11).

Our study has some limitations, i.e. only patients hospitalized at a single centre were included. Small study sample reduces the power of event-free survival analysis and the results obtained thus cannot be extrapolated to the overall population of ACS patients. Therefore, these data can only be used to generate some hypotheses, since they offer no evidence supporting the causative relationship; this would require confirmation in an appropriately randomized clinical trial.

In conclusion, vitamin D deficiency is present in the majority of ACS patients, with the lowest vitamin D level measured in diabetic ACS patients. During 3-year follow up, vitamin D failed to prove useful as a prognostic biomarker in ACS patients. However, the results obtained may prove relevant for public health by pointing to the issue, considering the high prevalence of vitamin D deficiency, aging of the population, polypragmasia contributing to low vitamin D levels, and sedentary lifestyle (25). Vitamin D deficiency can be treated and vitamin D supplementation is inexpensive; however, we should wait for the results of large randomized interventional studies that will determine whether CVD morbidity and mortality are reduced by vitamin D supplementation.

REFERENCES


Received September 30, 2015
Accepted in revised form July 25, 2016